Hoffmann-La Roche Inc.

C4 Therapeutics, Inc.

C4 Therepeutics, Inc.

F. Hoffmann-La Roche Ag

Roger David Norcross

Guido Galley

Katrin Groebke Zbinden

Emmanuel Pinard

Roland Jakob-Roetne

Philippe Pflieger

Alexander Flohr

Henri Stalder

Synese Jolidon

Robert Narquizian

Claus Riemer

Annick Goergler

Fabian Dey

Giuseppe Cecere

Matthias Heinrich Nettekoven

Eric Andre Kusznir

Raffaello Masciadri

Parichehr Malherbe

Philipp Schmid

Torsten Hoffmann

Alexander Alanine

Marius Hoener

Cornelia Hertel

Aubry Kern Miller

Sabine Kolczewski

Bernd Kuhn

Hasane Ratni

Georg Jaeschke

Christopher G Nasveschuk

Hong Shen

Yimin Hu

Thomas Johannes Woltering

Andrew William Thomas

Stephan Roever

Antonio Ricci

Cosimo Dolente

Sandra Steiner

Yvonne Alice Nagel

Eric Prinssen

Daniela Alberati-Giani

Edilio Borroni

Angelique Patiny-Adam

Alessandra Polara

Moreno Attilio Wichert

Cedric Ghellamallah

Adrian Britschgi

Daniela Alberati

Thomas Hartung

René Trussardi

Angélique Patiny-Adam

Gerda Huber Trottmann

David Hewings

Nicolas Zorn

Henri Stadler

Gavin John Kilpatrick

Gerda Huber-Trottmann

Phillippe Pfileger

Etienne Rauber

Alina Tirla

Edilio Maurizio Borroni

Daniel Rueher

Renè Trussardi

Cédric Ghellamallah

Rene Trussardi

Christa Ulrike Obst-Sander

The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Dihydrobenzimidazolones for medical treatment

The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Spirocyclic compounds

The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Dihydroquinolinones for medical treatment

The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Glutarimides for medical treatment

The invention relates to compounds of formula wherein R, R, R, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

Substituted benzamides

The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.

Morpholine derivative

The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors. 

Dimeric compounds

The present invention relates to compounds of formula of formula I wherein R, R, Rand L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I. 

Substituted pyrazino[2,2-a]isoquinoline derivatives

Growing community of inventors

Rheinfelden, Switzerland

Roger David Norcross